Testosterone Composition for Oral Delivery Treats Hypogonadism
Summary
The USPTO has published a patent application (US20260083755A1) assigned to NEUROCRINE UK LIMITED for a testosterone-containing pharmaceutical composition adapted for oral delivery. The application details treatment regimens and methods for hormone-related conditions like hypogonadism in human subjects.
What changed
This document is a publication of a United States Patent Application (US20260083755A1) filed by NEUROCRINE UK LIMITED. The application discloses a pharmaceutical composition for oral delivery containing native testosterone, along with treatment regimens and methods for addressing hormone-related conditions, specifically hypogonadism, in male, female, and transgender subjects.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property and market exclusivity for the assignee in the development and commercialization of such pharmaceutical compositions. Companies in the pharmaceutical sector, particularly those involved in hormone replacement therapies, should be aware of this filing as it may impact their R&D strategies and competitive landscape.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION
Application US20260083755A1 Kind: A1 Mar 26, 2026
Assignee
NEUROCRINE UK LIMITED
Inventors
Martin Whitaker, John Porter, Richard Ross, Stewart Jones, Elizabeth Cocks
Abstract
We disclose a pharmaceutical composition adapted for oral delivery comprising native testosterone; a treatment regimen comprising administration of the composition(s); and methods and uses for the treatment of hormone related conditions such as hypogonadism in human male, female and transgender subjects.
CPC Classifications
A61K 31/568 A61K 9/48 A61K 47/10 A61K 47/44 A61P 5/26
Filing Date
2025-12-03
Application No.
19407268
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.